74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Minerva Neurosciences Inc
Closed
6.58 -3.38
Overview
Share price change
24h
Min
6.49
Max
6.73
Income | -281M -284M |
|---|---|
P/E Sector Avg | 2.462 60.328 |
EPS | -0.36 |
Employees | 7 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +59.57% upside |
Next Earnings | 11 May 2026 |
|---|
Market Cap | -54M 250M |
|---|---|
Previous open | 9.96 |
Previous close | 6.58 |
Minerva Neurosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Minerva Neurosciences Inc Forecast
Price Target
By TipRanks
59.57% upside
12 Months Forecast
Average 10.5 USD 59.57%
High 14 USD
Low 7 USD
Based on 2 Wall Street analysts offering 12 month price targets forMinerva Neurosciences Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Pre-tax profit
Sales
Interest expense on debt
Operating profit
$
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Live chat